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Evaluation of a vaccine against Mannheimia haemolytica and 
Pasteurella multocida in sheep 
 
 
Of the 20 currently identified species in the genus Pasteurella, Mannheimia 
haemolytica (formerly called Pasteurella haemolytica) and Pasteurella multocida 
are the most important respiratory pathogens affecting domestic ruminants, 
especially in sheep and cattle, together causing fibrinous, necrotic pneumonia. 
This disease, commonly called “shipping fever”, is a leading cause of economic 
loss in the sheep industry. Factors such as transportation, viral infection, and 
overcrowded housing, may predispose the opportunistic infection by the pathogen. 
At present, several commercial vaccines have been developed to control 
pasteurellosis in sheep, including types such as bacterins, live attenuated, 
leukotoxin, capsule, lipopolysaccaride, subunit vaccines, sodium salicilate extract 
and potassium thiocyanate. Previous studies have shown that effective specific 
antibody response against M. haemolytica whole-cell antigen could be achieved 
via vaccination. However, for P. multocida, vaccines did not induce strong specific 
antibody response and some reports even suggested an increase in severity of 
infection by P. multocida after vaccination.   
  In this study, the efficacy of an autogenous vaccine made from antigens from 
both  M. haemolytica and P. multocida, was evaluated by measuring specific 
serum antibody titers produced against both bacteria in immunized sheep. Lambs 
were vaccinated on Nov. 23 and sera were obtained from all control (unvaccinated) 
and vaccinated animals on Nov. 16, Nov. 30, Dec. 7 and Dec. 14. The results 
showed that the vaccine induced significant antibody response against M. 
haemolytica in both ewes and rams after 7 days post vaccination. For the 
response to P. multocida, specific antibodies were induced in ewes; however, the 
vaccine failed to stimulate specific antibody production against P. multocida in 
rams.  
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1. Introduction 
Mannheimia haemolytica (formerly called Pasteurella haemolytica) and 
Pasteurella multocida are known to be the most prominent pathogens in the family 
Pasteurellaceae causing great economic losses in the domestic animal industry 
[1] [2]. Of the various M. haemolytica strains, M. haemolytica serotype A2 is the 
major pathogen responsible for diseases in sheep, causing a fibrinous, necrotic 
pneumonia, also called “shipping fever”. But this strain was not as 
well-characterized as strain A1, which mainly causes pneumonia in cattle [2]. 
Factors such as transportation, viral infection, and overcrowded housing, may 
also facilitate the opportunistic infection by the pathogen [3]. P. multocida was 
found present in lung lesions of sheep affected by pneumonia as well [4] [5], but 
due to its high antigenic variability, its molecular pathogenic mechanisms still 
remain to be investigated [6]. 
Our experiment was part of a long-term project to develop and tested the 
effectiveness of an autogenous vaccine to prevent pneumonia in young lambs. 
The vaccine was developed from antigens of both M. haemolytica and  P. 
multocida. The goal of this experiment was to test this vaccine’s efficacy in 
inducing specific antibody responses to the two bacteria in both ewe lambs and 
ram lambs. 
Currently there are two types of serological tests for evaluating vaccine 
efficacy against M. haemolytica and P. multocida. One is the leukotoxin   6
neutralization test (LNT) and the other is an ELISA test. Mosier et al. 1986 [14] 
showed that ELISA was a more convenient and faster tool compared with LNT. In 
this experiment, we measured the level of serum antibodies against both M. 
haemolytica and P. multocida using a whole-cell ELISA assay [15]. 
 
2. Review of Literature 
At present, several commercial vaccines have been developed to control 
pasteurellosis in sheep. For example, Once PMH, One Shot, Presponse, use 
antigens including bacterins, leukotoxin, capsule, different surface antigens and 
lipopolysaccaride [7] [8] [15]. However, researchers found that each vaccine 
induced variable levels of protection in response to different bacteria strains. 
Diker et al. 2000 [15] reported monovalent combined immunogens induced high 
antibody titers against homologous serotypes, but low titers against heterologous 
serotypes; and antigens from M. haemolytica Serotype A1 and A7 were found to 
be more antigenic than A2 and T4. There were also species differences in vaccine 
efficacy with variability in the induction of protective response in sheep and cattle 
seen [12]. 
Previous studies have shown that effective specific antibody response against 
M. haemolytica whole-cell antigen could also be achieved via vaccination. 
Mehmet Akan et al. 2006 [9] reported One Shot Ultra 8 vaccine induced specific 
antibody production against M. haemolytica using ELISA tests, with higher   7
specific antibody titers in vaccinated groups than in control groups. In addition, 
LNT (leukotoxin neutralization test) also revealed a higher specific antibody titer in 
vaccinated sheep compared to unvaccinated sheep. The study also evaluated 
lung lesion scores of both vaccinated and control animals and statistically 
significant differences (P<0.001) were observed between the vaccinated and 
control groups, with fewer lesion in the vaccinated groups. S. Srinand et al 1996 
[10] examined the efficacy of four vaccines: ‘One Shot’ (SmithKline Beecham, 
West Chester, PA, a bacterin-toxoid), ‘Presponse’ (Langford Laboratories, Guelph, 
Ontario, an Lkt-rich culture supernatant), ‘Once PMH’ (BioCor Inc., Omaha, NE, a 
modified live vaccine), and ‘Septimune’ (Fort Dodge laboratories, Fort Dodge, IA, 
an outer membrane extract). The study showed that ‘One Shot’, and ‘Once PMH’ 
vaccinated animals showed a significant (P < 0.05) increase in antibody levels 
against leukotoxin at 28 days post vaccination. ‘Once PMH’ vaccinated animals 
also showed significant (P < 0.05) increase in antibody levels against IROMPs 
(iron regulated outer membrane proteins) at 28 days after vaccination compared 
to the other groups. ‘Presponse’, ‘Once PMH’, and ‘One Shot’ vaccinated animals 
showed a significant (P < 0.05) increase in antibody levels against CP (capsular 
polysaccharide) over time. These groups also had significantly higher antibody 
levels against CP, compared to controls and ‘Septimune’ vaccinated at 14 and 28 
days (P < 0.05). 
However, other studies suggested that vaccination did not effectively protect   8
sheep from infection. Chandrasekaran S et al. 1991 [11] tested an oil adjuvant 
vaccine incorporating locally isolated strains of M. haemolytica type 7 and P. 
multocida types A and D, and found that the vaccine significantly reduced the lung 
lesions at P<0.05 level in vaccinated sheep compared with the control groups 
when all animals were challenged with M. haemolytica alone. However, when 
animals were challenged with P. multocida or the combination of M. haemolytica 
and P. multocida, the vaccine failed to induce significant levels of protection in 
vaccinated animals. Interestingly, the study also compared the efficacy of a 
commercial vaccine named Carovax (Wellcome Laboratories, UK, antigen 
information unavailable, protecting sheep and pigs from M. haemolytica) with this 
oil adjuvant vaccine containing locally isolated bacteria strains and found the 
Carovax vaccine did not produce any significant reduction in lung lesions caused 
by M. haemolytica and/or P. multocida. This observation indicated that geological 
differences in terms of isolation of bacteria strains could also influence the efficacy 
of vaccine, which would further complicate the development of a vaccine which 
could protect sheep from diverse strains of the bacteria. E. F. Cassirer et al. 2001 
[12]  tested whether a combination of an experimental P. trehalosi and M. 
haemolytica vaccine and a commercially-available bovine P. multocida and M. 
haemolytica vaccine would increase lamb survival following a pneumonia 
epidemic. They found that lamb survival differed among flocks (range 22% to 
100%), and, unexpectedly, survival of lambs born to vaccinated ewe lambs was   9
lower (P = 0.08) than survival of lambs born to unvaccinated ones. Antibody titers 
were high in ewes prior to vaccination, and vaccines failed to enhance antibody 
titers in treated ewes. None of the lambs born to vaccinated ewe lambs survived. 
These data suggested that, using existing technology, vaccinating ewe lambs 
following pneumonia epidemics would have little chance of increasing neonatal 
survival and population recovery, for example, in bighorn sheep.   
Currently there is no effective vaccine that protects sheep from strains of both 
M. haemolytica and  P. multocida or strains derived from different geological 
origins. However, given the significant economic losses due to sheep pneumonia 
that is caused by these two bacteria, it is necessary to develop such a vaccine for 
the benefits of sheep industry. It is likely that this can be realized. Jerry K. 
McVicker et al. 2002 [13] indicated the development of an effective vaccine could 
be possible based on the fact that animals that were naturally infected did develop 
resistance to subsequent infection.   
 
3. Materials and Methods 
3.1 Animals 
Sheep were from flocks at the Cornell Sheep Farm, composed of Dorsets and 
Finnsheep. Twenty ewe lambs and twenty ram lambs born in August 2005 were 
randomly selected and weaned on October, 2005. Blood samples were obtained 
from each animal on November 16 before vaccination. On November 23, 10   10
randomly selected ewes and 10 randomly selected rams were vaccinated, while 
an additional 10 animals of each sex comprised control groups. Blood samples 
were obtained from both control and vaccinated animals on November 30, 
December 7 and December 14. 
3.2  M. haemolytica and P. multocida vaccine preparation 
The vaccine used in this study was prepared by Dr. Yung-Fu Chang at the 
Animal Health Diagnostic Center of Cornell University. Isolates of Mannheimia 
haemolytica and Pasteurella multocida were obtained from Cornell lambs dying of 
pneumonia. They were grown in culture and then killed and enriched for 
leukotoxin (the toxin produced by the bacteria that causes lung damage) to create 
the bacterin. The vaccine was expected to produce antibodies and prime 
cell-mediated immune responses against both bacterial antigens and leukotoxin.   
3.3  M. haemolytica and P. multocida antigen preparation for 
ELISA tests 
We prepared whole-cell antigens of both bacteria for ELISA testing. Both 
bacteria were streaked onto BHI (Brain heart infusion broth) agar and then 
collected separately into formaldehyde (4%) containing peptone water. After being 
washed three times in phosphate buffered saline (PBS), the cell collection was 
diluted to10
8 bacteria/ml for use in the assay [9] [15]. 
3.4 ELISA tests for specific antibody 
Bacteria prepared in 3.3 were diluted to 10
6 cells per ml into carbonate coating   11
buffer (0.05M Na2CO3, 0.05M NaHCO3, pH 9.6). Each was then dispensed into 
the wells of an Immunolon 1B plate (Thermo Fisher Scientific Inc, Waltham, MA) 
in a volume of 50µl per well. After overnight incubation at 4°C, the plates were 
washed twice with PBS containing 1% Tween20 and twice with PBS. Then serum 
samples that had been serially diluted from 1/40 to 1/1280 into PBS containing 
0.05% Tween 20, were added in duplicate to the wells, at 50µl per well. After 
overnight incubation at 4°C, the plates were washed as described above. Then 
50µl anti-sheep IgG conjugated to alkaline phosphatase (Sigma Chemical Co., St. 
Louis, MO) diluted 1:1000, was added to each well [9] [15]. The plates were 
incubated overnight again and then washed as before. Finally, p-nitrophenyl 
phosphate substrate (Sigma Chemical Co., St Louis, MO), with 1mM of MgCl2 was 
added to each well in a volume of 50µl per well. Absorbance values were read at 
OD 405 nm after 20 min incubation by an ELISA reader. 
3.5 Statistical analysis 
Specific antibody titers in control and vaccinated sera were evaluated. We 
used JMP data-analysis software to analyze our data; Fit Model tests examined 
the regression relationship between two variables. The null hypothesis of the Fit 
Model is that two variables are independent of each other. When P<0.05, the null 
hypothesis is rejected. 
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4  Results and Discussions 
4.1 Determination of specific antibody titers   
We did not have access to serum samples from known affected lambs; 
therefore we had to determine ELISA titers using another approach. We reasoned 
that if the vaccine was effective in inducing specific antibody, we would expect 
that vaccinated animals would have higher specific antibody titers than control 
animals would. Similar to the methods described by Mehmet et al. [9], we 
determined the specific antibody titer as the reciprocal of the last dilution of each 
serum sample that gave an OD that was greater than three standard deviations 
above the mean value of the OD of sera from control sheep at the 1: 1280 dilution 
(Table 1-8). 
 
Table 1 Development of specific antibody titers against M. haemolytica over the four sampling dates in control ewes 
Dates/Control 
ewes’ ID 
1 2 5 9 10 12 15 19  24  35
Nov. 16  160  640 640 320 320 640 160 640  640  160
Nov. 30  160  80 320 160 160 320 160 80  640  80
Dec. 7  40  40 640 160 80 640 40 80  80  40
Dec. 14  40  160 80 80 80 160 80 160  640  80
 
Table 2 Development of specific antibody titers against M. haemolytica over the four sampling dates in vaccinated ewes 
Dates/Vaccinated 
ewes’ ID 
17 20 21 23 25 26 27 30 34 37
Nov. 16  320  1280 1280 640 320 320 320 320  160 320
Nov. 30  640  640 1280 1280 1280 1280 1280 1280  1280 1280
Dec. 7  160  320 1280 1280 1280 1280 640 160  40 320
Dec. 14  1280  640 640 640 640 640 640 320  640 320
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Table 3 Development of specific antibody titers against M. haemolytica over the four sampling dates in control rams 
Dates/Control 
rams’ ID 
3  71 31 42 82 93 13 3   3 84 0
Nov.  16  160 80 320 40 320 320 320 40 80 40
Nov. 30  40  160 640 160 320 320 320 80  40 40
Dec.  7  160 160 160 160 160 160 160 160 320 160
Dec. 14  320  40 640 160 320 160 320 320  320 80
 
Table 4 Development of specific antibody titers against M. haemolytica over the four sampling dates in vaccinated rams 
Dates/Vaccinated 
rams’ ID 
4 6 8 11 16 18 22 32  36 39
Nov. 16  1280  1280 640 640 640 320 320 640  320 320
Nov.  30  1280 1280 1280 1280 1280 1280 1280 1280 1280 1280
Dec.  7  640 40 40 40 40 40 40 40 40 40
Dec.  14  1280 1280 1280 1280 1280 320 1280 1280 1280 1280
 
Table 5 Development of specific antibody titers against P. multocida over the four sampling dates in control ewes 
Dates/Control 
ewes’ ID 
1  2 5 9 10 12 15 19 24 35
Nov.  16  640  320 640 320 640 320 160 640 320 320
Nov.  30  160  160 320 160 160 320 320 160 640 320
Dec. 7  40  80 640 160 80 160 40  80  320 160
Dec.  14  80  320 320 160 160 320 320 640 320 320
 
Table 6 Development of specific antibody titers against P. multocida over the four sampling dates in vaccinated ewes 
Dates/Vaccinated 
ewes’ ID 
17 20 21 23 25 26 27 30 34 37
Nov.  16  640 640 320 1280 320 1280 1280 640 640 640
Nov. 30  1280  1280 640 1280 640 1280 640  640  1280 1280
Dec.  7  40 160 160 320 160 320 80 160  80 160
Dec.  14  1280 1280 1280 1280 1280 640 1280 1280 1280 1280
 
Table 7 Development of specific antibody titers against P. multocida over the four sampling dates in control rams 
Dates/Control 
rams’ ID 
3  71 31 42 82 93 13 3   3 84 0
Nov. 16  40  80 80 80 40 80 80 40  320 40
Nov.  30  160 320 640 320 320 640 160 160 160 80
Dec. 7  160  160 640 320 320 640 160 40  80 160
Dec.  14  640 160 640 160 640 320 320 320 320 320
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Table 8 Development of specific antibody titers against P. multocida over the four sampling dates in vaccinated rams 
Dates/Vaccinated 
rams’ ID 
4 6 8 11 16 18 22  32  36 39
Nov.  16  320 320 320 320 160 320 320 320 160 80
Nov.  30  320 320 320 320 640 160 160 320 320 320
Dec. 7  1280  80 320 80 160 80 40  160  80 40
Dec. 14  1280  160 320 160 160 160 320  80  320 160
 
4.2 Data analysis and discussion 
ELISA titer values were analyzed by the Fit Model tests of JMP. We examined 
regression relationship of specific antibody titer with each of the three variables: 
treatment (control or vaccination), sex (ewes or rams) and dates of sampling (Nov. 
16, Nov. 30, Dec. 7 and Dec. 24).   
4.2.1 Vaccine efficacy against M. haemolytica 
4.2.1.1 Factors affecting specific antibody titers against M. haemolytica 
Models showed that the vaccine did induce significantly (P<.0001<.05) 
increased levels of specific antibodies against M. haemolytica in vaccinated 
lambs over unvaccinated animals. We also found that there was a significant 
regression relationship (P<0.0001<0.05) between the dates of sampling and 
specific antibody titers. However, there was no difference in specific antibody 
titers (P=0.9067>0.05) between ewe lambs and ram lambs. 
4.2.1.2 Discussion of vaccine efficacy against M. haemolytica 
(1) Interaction between treatment and dates of sampling in Ewes 
According to Figure 1, after vaccination on Nov. 23, specific antibody titers   15
peaked on Nov. 30, and were much higher than the titers on Nov. 16. However, 
the titer decreased sharply from Nov. 30 to Dec. 7, and then remained constant to 
Dec. 14. The specific antibody titer levels on Dec. 7 and Dec. 14 were still about 
100 titer units higher than that of ewes on Nov. 16 before vaccination. For control 
ewes, there was a slight decrease in specific antibody titer from Nov. 16 to Nov. 30, 
and then the titer remained constant during the remaining three sampling periods.   
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Figure 1 Development of specific antibody titers against M. haemolytica in ewes on Nov. 16, Nov. 30, Dec. 7 and Dec. 14.   
 
To understand the trends in more detail, we also analyzed the specific 
antibody titer development for each ewe over the entire sampling period (Figure 2 
and 3). In control ewes, specific antibody titers decreased in 7 out of the 10 
animals from Nov. 16 to Nov. 30. Since antibodies from passive transfer of 
colostrum usually existed in lambs for only one to two weeks, it was not likely that 
the decrease was due to colostrum antibody decline. Instead, we proposed that   16
the decline happened as a result of natural decrease of antibodies, which were 
probably induced by previous exposure or infection of M. haemolytica. Then from 
Nov. 30 to Dec. 7, 6 out of 10 control ewes’ titers were again slightly decreased 
and remained constant on Dec. 14. In vaccinated ewes, specific antibody titers 
increased sharply in 8 out of 10 vaccinated ewes from Nov. 16 to Nov. 30. On Nov. 
30, 8 out 10 animal’s titers were 1280 while the remaining two were 640. Titers 
then declined sharply in 6 ewes and remained the same in the remaining 4 
animals on Nov. 30 as on Dec. 7. Finally, from Dec. 7 to Dec. 14, titers decreased 
in 4 ewes, increased in 4 ewes and remained constant in the remaining 2 ewes. 
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Figure 2 Specific antibody titers development against M. haemolytica over the four sampling times in control ewes. The 
X-axis denotes the ID of control ewes and Y-axis shows specific antibody titers. 
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Figure 3 Specific antibody titers development against M. haemolytica over the four sampling dates in vaccinated ewes. The 
X-axis denotes the ID of vaccinated ewes and Y-axis shows specific antibody titers. 
 
  The results indicate that the autogenous vaccine did induce significant 
specific antibody production against M. haemolytica in the majority of the ewes 
immediately following vaccination.   
(2) Interaction between treatment and dates of sampling in Rams 
According to Figure 4, specific antibody titers in vaccinated rams were higher 
than that of control rams on all sampling dates except Dec. 7. For control rams, 
titers generally remained low and constant.     18
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Figure 4 Development of specific antibody titers against M. haemolytica in rams on Nov. 16, Nov. 30, Dec. 7 and Dec. 14.   
 
To understand the trends in more detail, we also analyzed specific antibody 
titer development in each ram over time (Figure 5 and 6). In the control group, 
specific antibody titer values in most of the rams were below 320 and there were 
no significant changes in titers over the four sampling times. In the vaccinated 
group, specific antibody titers in 8 out of 10 rams increased from Nov. 16 to Nov. 
30; on Nov. 30, the titers of all vaccinated rams were 1280. But the titers of all the 
rams declined sharply from Nov. 30 to Dec. 7. On Dec. 7, 9 out of the 10 
vaccinated rams’ titers dropped to 40 but rose again to 1280 in 9 vaccinated rams.   19
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Figure 5 Specific antibody titers development against M. haemolytica over the four sampling dates in control rams. The 
X-axis denotes the ID of control rams and Y-axis shows specific antibody titers. 
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Figure 6 Specific antibody titers development against M. haemolytica over the four sampling dates in vaccinated rams. The 
X-axis denotes the ID of vaccinated rams and Y-axis shows specific antibody titers. 
 
  The results showed that the vaccine also induced significant antibody 
production against M. haemolytica in rams, which declined quickly, within 1-2 
weeks. 
(3) Vaccine efficacy against M. haemolytica   20
There are several previous studies examining vaccine efficacy against whole 
cell antigens of M. haemolytica.  Srinand et al. [10] investigated antibody 
responses against M. haemolytica whole cell antigens in animals treated with four 
commercial vaccines and reported significant antibody level increases on day 28 
post vaccination at P<0.05 level in animals vaccinated with Once PMH, One Shot, 
Presponse.  Mehmet et al. [9] examined one vaccine’s efficacy in inducing 
specific antibodies against whole cell antigens of M. haemolytica in lambs 
(including both ewes and rams) three weeks post vaccination using ELISA tests, 
and found ELISA titers differed from 80 and 320, and between 160 and 320 in 
lambs vaccinated once and twice, respectively, while titers in unvaccinated 
controls were negative. Lung lesion scores were also compared and significant 
decreases were observed in the trials compared with control groups at P<0.001. 
In our study, we found that the overall production of specific antibody against 
M. haemolytica in both vaccinated ewe lambs and ram lambs was significantly 
higher than that of control lambs. This indicates that vaccination did induce 
specific antibody response in lambs, and agrees with the previous studies. In 
addition, in our study, vaccinated ewes had antibody titers at three weeks post 
vaccination ranging from 320 to 1280 (320 in 2 ewes, 640 in 7 ewes and 1280 in 1 
ewe). Compared with titers of vaccinated groups in Mehmet et al. study, the titer 
level in our study was higher. In control ewes in our study, titers were from 40 to 
640 (40 in 1 ewe, 80 in 5 ewes, 160 in 3 ewes and 640 in 1 ewe). Titers in 9   21
vaccinated rams were 1280; in control rams, titers ranged from 40 to 640 (40 in 1 
ram, 80 in 1 ram, 160 in 2 rams, 320 in 5 rams, and 640 in 1 ram). The fact that we 
were able to detect some antibody in control animals may have been due to 
natural infection or exposure.   
Interestingly, from Nov. 30 to Dec. 7, antibody titers in both vaccinated ewes 
and rams decreased dramatically. On Dec. 7, for vaccinated ewes, titers in all the 
other 6 ewes decreased except that 4 animals’ titers remained at the titer level of 
1280 as they were on Nov. 30. For vaccinated rams from Nov. 30 to Dec. 7, titers 
in 9 out of all 10 rams dropped from 1280 to 40. We may rule out the possibility of 
assay failure based on the fact that high antibody titers in sera taken on Dec. 7 
were detected in 4 ewes. Since all tests for sera on Dec. 7 were performed at the 
same time, if the assay had failed, there would have been no antibody detected in 
every sera sample. On the other hand, A.W. Confer et al. 2009 [16] also reported 
decrease of specific antibody against whole cell M. haemolytica antigens in 
vaccinated animals between Day 14 and Day 21 after vaccination, which 
remained constant after Day 21, but the average response still remained higher 
than that of control animals; we did not see this in the present study. For the 
vaccinated ewes and rams in our experiment, we proposed that the titer decline 
from Nov. 30 to Dec. 7 may have also been due to natural antibody decrease, 
which usually declined to basal level within 14 days. It is possible that the titer 
increase from Dec. 7 to Dec. 14 in vaccinated rams may have been induced by   22
exposure to M. haemolytica in the environment that would act as a booster, and 
induce a secondary immune response. This hypothesis is supported by the fact 
that the antibody titers against M. haemolytica in control rams, although slightly 
lower, also increased from Dec. 7 to Dec. 14, and again may have been due to 
exposure to the organism(s) in the environment.   
Finally, the results suggest there were no gender differences in antibody 
response against M. haemolytica induced by vaccination. 
 
4.2.2 Vaccine efficacy against P. multocida 
4.2.2.1 Factors affecting specific antibody titers against P. multocida 
The JMP model indicated that the vaccine did induce a significant increase 
(P<0.0001<0.05) in the production of specific antibody against P. multocida in 
vaccinated lambs over unvaccinated lambs. It also showed there was significant 
regression relationship (P<0.0001<0.05) between sex and specific antibody. In 
addition, titers of specific antibodies varied significantly (P<0.0001<0.05) across 
the four sampling dates. 
4.2.2.2 Discussion of vaccine efficacy against P. multocida 
(1) Interactions between treatment and dates of sampling in Ewes 
In Figure 7, the specific antibody titers in the vaccinated group were higher 
than the corresponding titers in the control group over the experimental period 
except on Dec. 7. After vaccination on Nov. 23, there was an increase in specific   23
antibody titer on Nov. 30, compared to Nov. 16, and also that of titers in the control 
group. However, there was a sudden titer decrease on Dec. 7, and a sharp 
increase followed on Dec. 14 for vaccinated sera. In the control group, the titer 
decreased from Nov. 16 to Dec. 7.   
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Figure 7 Development of specific antibody titers against P. multocida in ewes on Nov. 16, Nov. 30, Dec. 7 and Dec. 14.  
 
To understand the trend in more detail, we analyzed the specific antibody titer 
in each ewe over time (Figures 8 and 9). In control ewes, from Nov. 16 to Nov. 30, 
titers in 6 out of 10 animals decreased, while titers for two animals increased and 
the remaining two were unchanged. Then from Nov. 30 to Dec. 7, titers decreased 
again in 8 animals. Finally, titers increased from Dec. 7 to Dec. 14 in 7 out of 10 
animals. The titer on Dec. 14 was close to that on Nov. 30. Since antibodies from 
passive transfer of colostrum usually existed in lambs for only one to two weeks, it 
was not likely that the titer level decline in the majority of control ewes from Nov. 
16 to Nov. 30 was due to colostrum antibody decrease. Instead, we proposed that   24
the decline happened as a result of natural decrease of antibodies, which were 
probably induced by previous exposure or infection of P. multocida. In vaccinated 
ewes, titers increased from Nov. 16 to Nov. 30 in 6 out of 10 animals, while titers in 
three ewes remained the same and one decreased. On Nov. 30, titers for 6 ewes 
were 1280 and that of the remaining four were 640. Then titers decreased sharply 
from Nov. 30 to Dec. 7 in all 10 animals and titers on Dec. 7 ranged from 40 to 320. 
Finally, titers increased in all animals from Dec. 7 to Dec. 14, to 1280 in 9 animals 
on Dec. 14.   
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Figure 8 Development of specific antibody titers against P. multocida in control ewes over the four sampling dates. The 
X-axis denotes the ID of control ewes and the Y-axis shows the specific antibody titers. 
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Figure 9 Development of specific antibody titers against P. multocida in vaccinated ewes over the four sampling dates. The 
X-axis denotes the ID of vaccinated ewes and the Y-axis shows specific antibody titers. 
 
The results indicated that the vaccine did induce strong specific antibody 
production against P. multocida in ewes, which declined quickly in 1-2 weeks.   
(2) Interactions between treatment and dates of sampling in Rams 
In Figure 10, there was no significant difference in specific titers between 
vaccinated ram lambs and control ram lambs over the four sampling dates. 
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Figure 10 Development of specific antibody titers against P. multocida in rams on Nov. 16, Nov. 30, Dec. 7 and Dec. 14.   
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To understand the phenomenon in more details, we also analyzed the 
development of specific antibody titers in each ram over the four sampling dates 
(Figures 11 and 12). Specific antibody titers in almost all vaccinated animals 
across the four sampling times were below 400. Unexpectedly, more 
unvaccinated rams had titers greater than 400 compared to vaccinated rams. Also, 
after immediate vaccination titers were increased only in three vaccinated rams, 
from Nov. 16 to Nov. 30.   
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Figure 11 Development of specific antibody titers against P. multocida in control rams over the four sampling dates. The 
X-axis denotes the ID of control rams and the Y-axis shows specific antibody titers. 
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Figure 12 Development of specific antibody titers against P. multocida in vaccinated rams over the four sampling dates. 
The X-axis denotes the ID of vaccinated rams and the Y-axis shows the specific antibody titers. 
 
The result indicated that the vaccine failed to induce significant specific 
antibody response in rams. 
(3) Vaccine efficacy against P. multocida 
Several previous studies investigated the efficacy of vaccination against P. 
multocida and found that vaccination against P. multocida was not as effective as 
against  M. haemolytica.  Chandrasekaran S et al. 1991 [11] tested an oil 
adjuvant vaccine incorporating antigens from both M. haemolytica and P. 
multocida, and reported significant pneumonic lesion reduction in vaccinated 
lambs after challenge with M. haemolytica, but not after challenge with P. 
multocida. Carmen et al. 1983 [17] argued that the limited protection of specific 
antibody against P. multocida via vaccination was probably because P. multocida 
strains did not share universal antigens, and they proposed that finding a new   28
strain with wide spectrum of antigens would help solve this problem.   
  According to the data presented in section 4.2.2.2, we observed significant 
overall specific antibody response against P. multocida in vaccinated ewes 
compared with control ewes, while there were no significant differences between 
titers of control rams and vaccinated rams. The results indicated a gender 
difference in specific antibody response against P. multocida vaccines. The exact 
reason for gender difference in antibody response to vaccination is still uncertain, 
but several studies have shown that some immune responses in humans are 
higher in females compared to males, including numbers of CD4+ T cells [18] [19] 
[20] [21]. In particular, Alberto Amadori et al. 1995 [19] examined CD4 and CD8 
T cell numbers in healthy donors and reported the CD4/CD8 T cells ratio was 
significantly higher in females than that in males, which, they proposed, was due 
to genetic regulation in humans. Bret J. Rudy et al. 2002 [21] performed flow 
cytometry analysis of lymphocyte subset markers on a group of sexually active, 
human immunodeficiency virus (HIV)-negative adolescents, and found that 
females had higher total CD4+ T cell and CD4+ memory T cell counts compared 
to males. These observations suggest, at least in part, why females may have 
responded better than males in terms of antibody production. Furthermore, the 
function of these T cells (TH1 or TH2) rather than number, may also be important 
[22]. In addition, considering the differences in the immune systems of humans 
and sheep, other factors may play a role in the gender differences in antibody   29
response in lambs. 
  Interestingly, the antibody titer in vaccinated ewes declined sharply from Nov. 
30 to Dec. 7. On Nov. 30, titers for 6 vaccinated ewes were 1280 and the other 4 
ewe’s titers were 640. On Dec.7, titers were as low as 40 to 320. The possibility 
that the ELISA assay failed was ruled out because other samples that were tested 
in the same assay showed significant antibody titers. It is possible that sampling 
or storage issues may have resulted in our inability to detect specific antibody in 
the sera of vaccinated ewes. It is also possible that the titer decline may have 
been due to a natural decrease in sera antibody levels, and the titer surge from 
Dec. 7 to Dec. 14 represented a secondary immune response induced by a 
natural P. multocida infection or exposure. This is supported by the fact that the 
vaccinated ewes’ antibody titer on Dec. 24 was higher than that on Dec. 7. The 
slight titer increase that we noted in sera from Dec. 7 to Dec. 14 in both 
vaccinated and control rams, suggests that a natural infection or exposure to P. 
multocida may have occurred on the farm around Dec. 7.     
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6. Appendix 
6.1 Raw data from ELISA tests 
Table 1 Absorbance of Control Ewes serum samples against M. haemolytica on Nov. 16 
 
Animal 
I D            
Dilutions 1 2 5 9 10 12 15  19  24 35
40  0.1534 0.2076 0.1975 0.2411 0.2124 0.1607 0.1466 0.1588 0.2172 0.1311
80  0.1246 0.1956 0.2143 0.1809 0.1739 0.1694 0.1373 0.1215 0.1427 0.1271
160  0.1239 0.1522 0.1526 0.1521 0.1438 0.0711 0.1144 0.1371 0.1432 0.1405
320 0.0913  0.1399  0.121 0.1434 0.1267 0.1511 0.0918 0.1349 0.1616 0.0899
640  0.0888 0.1096 0.1111 0.1014 0.0939 0.1272 0.072 0.1096 0.1346 0.1125
1280  0.0768 0.0987 0.0822 0.0885 0.0829 0.0993 0.0712 0.0789 0.0941 0.0744
blank  0.0662 0.0632 0.0642 0.0602 0.0589 0.0997 0.0631 0.0602 0.0548 0.0561
  
Table 2 Absorbance of Vaccinated Ewes serum samples against M. haemolytica on Nov. 16 
 
Animal 
I D            
Dilutions  19 20 21 23 25 26 27 30 34 37
40  0.1837 0.2083 0.2032 0.2074 0.2132 0.2304 0.2009 0.206 0.133 0.1498
80 0.1581  0.1847  0.176 0.1966 0.1401 0.1949 0.1583 0.151  0.1238 0.1569
160  0.1313 0.1666 0.1775 0.1687 0.1342 0.1353 0.1555 0.1364  0.113 0.1434
320  0.1762 0.1451 0.1232 0.138 0.1057 0.1051 0.1308 0.1147 0.0993 0.1044
640  0.1023 0.1778 0.1584 0.1428 0.0922 0.0979 0.1023 0.091 0.101 0.0924
1280  0.0946 0.1662 0.1397 0.0889 0.0805 0.0921 0.0922 0.0911 0.0752 0.0804
blank  0.1045 0.0807 0.0831 0.0679 0.0658 0.0724 0.0647 0.07  0.0627 0.0634
 
Table 3 Absorbance of Control Ewes serum samples against P. multocida on Nov. 16 
 
Animal 
I D            
Dilutions 1 2 5 9 10 12 15  19  24 35
40  0.3599 0.3809 0.5181 0.3229 0.2511 0.4124 0.5713 0.2885 0.4469 0.2626
80  0.2304 0.2652 0.3546 0.2811 0.3662 0.3526 0.3335 0.2497 0.2938 0.277
160  0.1566 0.1677 0.2832 0.246 0.2155 0.2207 0.2044 0.184  0.2397 0.2254
320 0.1244  0.148  0.2188 0.2361 0.2297 0.1748 0.1354 0.1604 0.1539 0.1499
640 0.1443  0.1255  0.152 0.1348 0.1507 0.1397 0.1332 0.1472 0.0976 0.1232
1280  0.0872 0.0949 0.1086 0.1149 0.1115 0.1063 0.0954 0.0962 0.1007 0.063
blank  0.0642 0.0759 0.0656 0.0703 0.0823 0.0652 0.0659 0.0679 0.0695 0.0695
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Table 4 Absorbance of Vaccinated Ewe serum samples against P. multocida on Nov. 16 
 
Animal 
I D            
Dilutions 19 20 21 23 25 26 27 30 34 37
40  0.3718 0.4412 0.4122 0.3645 0.3798 0.4079 0.4261 0.3784 0.3081 0.2369
80  0.3283 0.2968 0.3264 0.382 0.3324 0.3328 0.34 0.2839 0.2394 0.2389
160  0.262 0.2472 0.2304 0.3401 0.245 0.2504 0.2475 0.2404 0.1953 0.2096
320 0.2368  0.2229  0.159 0.253 0.2548 0.2163 0.274 0.2306 0.2103 0.2115
640 0.1751  0.1695  0.126 0.2168 0.1342 0.1697 0.1793 0.1737 0.1556 0.1681
1280 0.122  0.1317  0.103 0.1544 0.1353 0.1517 0.1528 0.125  0.1159 0.1251
blank  0.0699 0.0686 0.0675 0.0689 0.0713 0.0713 0.0722 0.0729 0.0741 0.0708
 
Table 5 Absorbance of Control Ewe serum samples against M. haemolytica on Nov. 30 
 
Animal 
I D            
Dilution 1 2 5 9 10 12 15  19  24 35
40  0.1053 0.1132 0.1133 0.0954 0.0896 0.0872 0.0891 0.0861 0.1028 0.0877
80  0.0894 0.0997 0.1012 0.092 0.0833 0.0902 0.0837 0.0813  0.091 0.0883
160  0.0828 0.0811 0.0826 0.0874 0.0839 0.0877 0.0824 0.0772 0.0866 0.0795
320  0.0715 0.0794 0.0822 0.0777 0.0728 0.0819 0.0713 0.0739 0.0839 0.0759
640  0.0678 0.0741 0.0754 0.079 0.0726 0.0776 0.0699 0.0712 0.0853 0.0795
1280  0.0673 0.0681 0.0732 0.0753 0.0671 0.0755 0.0695 0.0731 0.0744 0.067
blank  0.0645 0.0657 0.0591 0.0609 0.0653 0.0579 0.0726 0.0681 0.0729 0.0736
 
Table 6 Absorbance of Vaccinated Ewe serum samples against M. haemolytica on Nov. 30 
 
Animal 
I D            
Dilution 17 20 21 23 25 26 27 30 34 37
40  0.3998 0.1339 0.1139 0.107 0.1084 0.111 0.1077 0.1417 0.1724 0.1843
80  0.1039 0.1391 0.1515 0.107 0.0937 0.1113 0.1052 0.2014 0.1323 0.1752
160 0.088  0.1044  0.107 0.1077 0.0942 0.0967 0.0973 0.1613 0.1297 0.1462
320  0.099 0.0967 0.1021 0.096 0.0938 0.0985 0.0858 0.1534 0.1097 0.1422
640 0.1112  0.1018  0.096 0.0957 0.0844 0.0862 0.0958 0.1079 0.0865 0.1093
1280  0.078 0.0788 0.0878 0.0904 0.0877 0.08 0.086 0.0985 0.0819 0.0989
blank  0.0607 0.0573 0.0587 0.0682 0.0687 0.0638 0.059 0.0676 0.0624 0.0618
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Table 7 Absorbance of Control Ewe serum samples against P. multocida on Nov. 30 
 
Animal 
I D            
Dilution 1 2 5 9 10 12 15  19  24 35
40  0.191 0.1993 0.2943 0.1975 0.222 0.2917 0.2117 0.217  0.2525 0.2209
80  0.1628 0.1668 0.2524 0.1798 0.1773 0.2121 0.1874 0.2005 0.2334 0.1466
160  0.1434 0.1267 0.1805 0.1433 0.1386 0.1551 0.1664 0.1254 0.1749 0.1687
320 0.1108  0.1002  0.15 0.1081 0.1064 0.1425 0.1438 0.1327  0.17 0.1412
640  0.096 0.0842 0.1148 0.095 0.0889 0.1181 0.1201 0.1172 0.1471 0.109
1280 0.0861  0.0864  0.102 0.0882 0.088 0.1183 0.1123 0.0846 0.1153 0.0889
blank 0.0647  0.0756  0.077 0.0784 0.0743 0.085 0.069 0.0615 0.0624 0.0592
 
Table 8 Absorbance of Vaccinated Ewe serum samples against P. multocida on Nov. 30 
 
Animal 
I D            
Dilution 17 20 21 23 25 26 27 30 34 37
40  0.3251 0.3068 0.2824 0.3193 0.2613 0.2983 0.2829 0.2377 0.3471 0.2433
80  0.2759 0.3075 0.3027 0.3056 0.2357 0.2609 0.2459 0.25  0.2713 0.1869
160 0.2494  0.239  0.1882 0.2509 0.2025 0.2293 0.2166 0.2051 0.2188 0.2066
320  0.1698 0.2083 0.1684 0.1987 0.1775 0.1893 0.1618 0.1645 0.1804 0.1827
640  0.1714 0.1784 0.1472 0.1617 0.1523 0.1449 0.1415 0.1434 0.1446 0.1373
1280 0.1398  0.1307  0.121 0.141 0.1164 0.1229 0.1138 0.1208 0.1254 0.1301
blank  0.0669 0.0629 0.0647 0.0715 0.0674 0.0618 0.0628 0.0648 0.0671 0.0611
 
Table 9 Absorbance of Control Ewe serum samples against M. haemolytica on Dec. 7 
  A n i m a l   I D          
Dilution 1 3 5 9 10 12 15  19  24 35
40  0.1049 0.1406 0.2397 0.1507 0.1679 0.1177 0.112 0.1322 0.1482 0.1418
80  0.0958 0.1118 0.1794 0.1215 0.1297 0.1683 0.1139 0.1352 0.1459 0.1066
160  0.0824 0.1171 0.1471 0.1245 0.108 0.1245 0.1088 0.1009 0.1104 0.0925
320  0.0811 0.1122 0.1524 0.1141 0.0956 0.1335 0.0945 0.0946 0.1168 0.0951
640  0.1035 0.1034 0.1211 0.1083 0.0933 0.1235 0.0904 0.1043 0.0995 0.0745
1280  0.0672 0.1027 0.1014 0.0911 0.0899 0.1072 0.0855 0.0904 0.1055 0.0766
blank 0.0625  0.0624  0.059 0.0577 0.056 0.0575 0.0634 0.0564 0.0575 0.0591
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Table 10 Absorbance of Vaccinated Ewe serum samples against M. haemolytica on Dec. 7 
 
Animal 
ID 
         
Dilution 17 20 21 23 25 26 27 30 34 37
40  0.1469 0.1841 0.2077 0.2717 0.118 0.1356 0.1275 0.155  0.1207 0.1353
80  0.1311 0.1876 0.1811 0.1606 0.12 0.1315 0.1228 0.1128 0.1089 0.1407
160  0.1252 0.1248 0.1498 0.1578 0.1145 0.1198 0.1267 0.1219 0.0998 0.1317
320  0.099 0.1258 0.1634 0.1742 0.1193 0.1096 0.1175 0.098  0.0904 0.1202
640  0.1024 0.1084 0.1512 0.1373 0.1313 0.1531 0.19 0.1043 0.0806 0.0909
1280  0.12 0.1158 0.1418 0.1413 0.125 0.1206 0.1122 0.1239 0.0809 0.0871
blank  0.0629 0.0731 0.0669 0.0504 0.061 0.0597 0.0573 0.0585 0.0576 0.0622
 
Table 11 Absorbance of Control Ewe serum samples against P. multocida on Dec. 7 
 
Animal 
ID 
         
Dilution 1 2 5 9 10 12 15  19  24 35
40 0.1872  0.186  0.3527 0.1985 0.2294 0.2189 0.1966 0.2225 0.2386 0.219
80  0.1384 0.1754 0.3474 0.1944 0.184 0.1645 0.163 0.1781 0.2193 0.2114
160  0.1216 0.1634 0.3102 0.1706 0.1504 0.2049 0.159 0.1634 0.1851 0.1741
320 0.0999  0.1182  0.245 0.158 0.1354 0.1612 0.1365 0.1378 0.1672 0.1481
640  0.0908 0.1086 0.1878 0.1211 0.143 0.1408 0.1228 0.1208 0.1269 0.125
1280 0.0786  0.092  0.1467 0.1032 0.0903 0.128 0.107 0.113  0.1065 0.1171
blank 0.0615  0.0601  0.061 0.0703 0.0577 0.0566 0.0568 0.0561  0.059 0.058
 
Table 12 Absorbance of Vaccinated Ewe serum samples against P. multocida on Dec. 7 
 
Animal 
ID 
         
Dilution 17 20 21 23 25 26 27 30 34 37
40  0.1919 0.2737 0.2689 0.2454 0.1627 0.2083 0.1801 0.2103 0.2078 0.1812
80  0.1277 0.2065 0.2553 0.1968 0.2031 0.1823 0.1721 0.1786 0.2019 0.1664
160 0.1263  0.169  0.1962 0.2056 0.176 0.1887 0.1483 0.1899 0.1461 0.1646
320  0.1287 0.1824 0.1555 0.1725 0.1587 0.1814 0.1417 0.1635 0.1272 0.1252
640  0.1134 0.1335 0.1313 0.142 0.1389 0.1373 0.1321 0.1185 0.1233 0.143
1280  0.1113 0.1377 0.1055 0.132 0.1356 0.1146 0.1139 0.1412 0.1059 0.129
blank  0.0659 0.0592 0.0592 0.0631 0.0582 0.0594 0.0595 0.0628 0.0606 0.0615
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Table 13 Absorbance of Control ewe serum samples against M. haemolytica on Dec. 14 
 
Animal 
I D            
Dilution 17 20 21 23 25 26 27 30 34 37
1:40    0.1855 0.2916 0.3401 0.248 0.215 0.2293 0.2756 0.286  0.4174 0.3026
1:80 0.155  0.231  0.4654 0.2192 0.232 0.2679 0.2327 0.2305 0.4113 0.247
1:160  0.1333 0.2183 0.1762 0.1719 0.1704 0.2423 0.1607 0.1929 0.3215 0.191
1:320  0.1056 0.1592 0.1422 0.1394 0.1513 0.1665 0.1567 0.1456 0.3517 0.1553
1:640 0.0903  0.149  0.1275 0.1123 0.122 0.1722 0.1259 0.1498 0.2355 0.1385
1:1280  0.0938 0.1127 0.0909 0.1038 0.0876 0.1518 0.1041 0.1117 0.1737 0.1119
Blank 0.0719  0.06  0.0636 0.06 0.0603 0.0603 0.0653 0.0644 0.0614 0.062
 
Table 14 Absorbance of Vaccinated Ewe serum samples against M. haemolytica on Dec. 14 
 
Animal 
I D            
Dilution 17 20 21 23 25 26 27 30 34 37
1:40  0.3932 0.4006 0.3977 0.5145 0.5558 0.4808 0.3239 0.34  0.5196 0.3196
1:80  0.3503 0.3336 0.3348 0.3472 0.3604 0.4006 0.3122 0.3952 0.4041 0.3119
1:160  0.2944 0.3388 0.3855 0.3307 0.3092 0.2705 0.2861 0.2386 0.3374 0.2308
1:320  0.2553 0.2326 0.2756 0.2502 0.2732 0.2296 0.2532 0.205  0.3516 0.2069
1:640 0.2207  0.21  0.2027 0.1975 0.2633 0.2211 0.1957 0.1476  0.213 0.1445
1:1280  0.2107 0.1671 0.1636 0.1679 0.1638 0.164 0.1265 0.1192 0.1605 0.1396
Blank  0.1182 0.0612 0.0626 0.063 0.0676 0.0646 0.0608 0.0604 0.0664 0.0694
 
Table 15 Absorbance of Control Ewe serum samples against P. multocida on Dec. 14  
 
Animal 
I D            
Dilution 1 2 5 9 10 12 15  19  24 35
1:40  0.2346 0.3487 0.5961 0.3806 0.3846 0.2895 0.3325 0.412  0.4374 0.341
1:80  0.1895 0.2771 0.4412 0.3081 0.3084 0.3145 0.3081 0.3465 0.2945 0.2606
1:160  0.1627 0.2413 0.2751 0.2205 0.225 0.2967 0.2316 0.2764 0.4374 0.231
1:320  0.1471 0.1962 0.1988 0.1719 0.1663 0.2516 0.2066 0.2747 0.2118 0.1845
1:640  0.0994 0.1474 0.1485 0.1581 0.1315 0.1345 0.1715 0.1904 0.1605 0.1783
1:1280  0.0834 0.1111 0.1184 0.1005 0.1114 0.1585 0.133 0.1361  0.139 0.1184
Blank  0.0638 0.0701 0.0635 0.0638 0.0637 0.0615 0.0641 0.062  0.0638 0.0618
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Table 16 Absorbance of Vaccinated Ewe serum samples against P. multocida on Dec. 14 
 
Animal 
I D            
Dilution 17 20 21 23 25 26 27 30 34 37
1:40  0.6754 0.6545 0.6587 0.5687 0.5977 0.6212 0.4785 0.3853 0.6574 0.4599
1:80  0.6479 0.6446 0.5406 0.4582 0.6354 0.4617 0.479 0.414  0.7461 0.4423
1:160 0.6011  0.5775  0.53 0.4598 0.3777 0.4067 0.4712 0.4353 0.5303 0.3934
1:320  0.318 0.4415 0.3686 0.4234 0.4204 0.3156 0.3321 0.4212 0.4804 0.3753
1:640  0.2771 0.3918 0.2423 0.3329 0.2851 0.2374 0.2705 0.2843 0.3117 0.3066
1:1280  0.4044 0.2493 0.2261 0.2644 0.2023 0.1728 0.2094 0.2118 0.2042 0.2003
Blank  0.0768 0.0725 0.0739 0.0909 0.0642 0.0648 0.0722 0.0628 0.0682 0.0703
 
Table 17 Absorbance of Control Ram serum samples against M. haemolytica on Nov. 16 
 
Animal 
I D            
Dilution  3  7 13 14 28 29 31 33 38 40
40  0.1018 0.1158 0.1766 0.1006 0.1138 0.1408 0.1653 0.104  0.1014 0.0965
80  0.1063 0.1093 0.1393 0.0916 0.1167 0.1153 0.1574 0.0929  0.123 0.095
160  0.1058 0.0943 0.1189 0.0869 0.1059 0.1425 0.138 0.0863 0.0906 0.0802
320  0.0848 0.1077 0.1852 0.0727 0.0995 0.1322 0.1197 0.1792  0.113 0.0725
640  0.112 0.0901 0.0887 0.0757 0.0865 0.0965 0.0965 0.0758 0.0842 0.0758
1280  0.0647 0.0815 0.0748 0.0826 0.0809 0.0809 0.0868 0.0647 0.0689 0.07
blank  0.0594 0.0612 0.0572 0.0707 0.0603 0.066 0.0627 0.0561  0.059 0.058
 
Table 18 Absorbance of Vaccinated Ram serum samples against M. haemolytica on Nov. 16 
 
Animal 
I D            
Dilution 4 6 8 11 16 18 22  32  36 39
40  0.2134 0.1379 0.1337 0.308 0.1319 0.1372 0.1209 0.1437 0.1284 0.1257
80  0.1791 0.1742 0.1174 0.1304 0.1343 0.146 0.1298 0.1066 0.1182 0.1027
160  0.1672 0.1197 0.1402 0.1393 0.1075 0.1203 0.1311 0.1124 0.1426 0.0832
320 0.1279  0.109  0.1277 0.1366 0.1052 0.1151 0.1669 0.1091  0.125 0.0995
640  0.1295 0.1089 0.1139 0.1986 0.0986 0.0947 0.0899 0.1034 0.0902 0.0826
1280  0.1153 0.2168 0.0929 0.0822 0.0851 0.0867 0.124 0.0879 0.0833 0.0627
blank  0.3601 0.1207 0.0738 0.0613 0.0676 0.0671 0.0762 0.0656 0.0958 0.084
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Table 19 Absorbance of Control Ram serum samples against P. multocida on Nov. 16 
 
Animal 
I D            
Dilution  3  7 13 14 28 29 31 33 38 40
40  0.1319 0.2144 0.1225 0.1681 0.1728 0.1897 0.157 0.1411  0.165 0.1594
80  0.1153 0.1409 0.1325 0.1305 0.12 0.1307 0.1426 0.1203 0.1288 0.1129
160  0.1122 0.1195 0.0997 0.1254 0.1279 0.1141 0.1257 0.1381 0.1331 0.0963
320  0.1234 0.0898 0.0892 0.0875 0.0922 0.1783 0.0881 0.0961  0.148 0.2139
640  0.0796 0.0827 0.0762 0.0804 0.0873 0.1011 0.0838 0.0818 0.1043 0.074
1280  0.0739 0.0837 0.0758 0.0723 0.0717 0.0785 0.0805 0.1275 0.0783 0.076
blank  0.0621 0.0611 0.0608 0.0617 0.0644 0.0722 0.0633 0.0625 0.1425 0.0614
 
Table 20 Absorbance of Vaccinated Ram serum samples against P. multocida on Nov. 16 
 
Animal 
I D            
Dilution 4 6 8 11 16 18 22  32  36 39
40  0.2624 0.2581 0.3064 0.2391 0.2047 0.259 0.2056 0.2551  0.161 0.2184
80  0.2295 0.2677 0.2212 0.1873 0.1779 0.1745 0.1847 0.1922  0.175 0.2397
160  0.1738 0.1716 0.1905 0.1897 0.142 0.1498 0.134 0.183  0.1883 0.1202
320 0.1455  0.141  0.1542 0.1301 0.109 0.1326 0.1707 0.1482 0.1147 0.1037
640  0.1202 0.1072 0.1037 0.104 0.0911 0.1248 0.0951 0.1216 0.0961 0.0963
1280  0.0918 0.0834 0.0856 0.1653 0.0992 0.084 0.0903 0.1101 0.0769 0.0739
blank  0.0766 0.0754 0.0599 0.0613 0.0708 0.062 0.063 0.1832 0.0665 0.0682
 
Table 21 Absorbance of Control Ram serum samples against M. haemolytica on Nov. 30 
  A n i m a l   I D          
Dilution  3  7 13 14 28 29 31 33 38 40
40 0.1291  0.202  0.1704 0.1414 0.1418 0.1773 0.1938 0.1325 0.1019 0.1084
80  0.1112 0.1459 0.1804 0.1302 0.1491 0.181 0.1608 0.1244 0.0989 0.0951
160  0.113 0.1194 0.1542 0.1142 0.129 0.1212 0.1537 0.1009 0.0965 0.081
320  0.1017 0.1086 0.1419 0.105 0.1146 0.145 0.1271 0.0972 0.0827 0.081
640 0.0862  0.103  0.1266 0.09 0.0954 0.0999 0.1058 0.089  0.0888 0.0799
1280  0.0767 0.0878 0.0942 0.096 0.0903 0.1015 0.0962 0.0864 0.0773 0.0844
blank  0.0771 0.0877 0.0714 0.0657 0.0763 0.062 0.0585 0.06  0.0619 0.0672
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Table 22 Absorbance of Vaccinated Ram serum samples against M. haemolytica on Nov. 30 
  A n i m a l   I D          
Dilution 4 6 8 11 16 18 22  32  36 39
40  0.6438 0.4355 0.4177 0.3714 0.4047 0.4053 0.4556 0.4926 0.2853 0.3761
80 0.6532  0.392  0.3481 0.3739 0.3191 0.2592 0.2805 0.3393 0.2723 0.2284
160  0.4124 0.3691 0.2947 0.3123 0.2958 0.201 0.2203 0.2605 0.2837 0.229
320  0.3862 0.2796 0.3069 0.2768 0.2382 0.2325 0.204 0.2561 0.2236 0.205
640  0.269 0.2512 0.2441 0.2367 0.1812 0.1645 0.1993 0.1931 0.2006 0.1585
1280  0.2184 0.1808 0.1908 0.1682 0.1698 0.1187 0.1968 0.1637 0.1676 0.1684
blank  0.0661 0.0641 0.0646 0.0822 0.0653 0.0685 0.0635 0.0661 0.0669 0.0652
 
Table23 Absorbance of Control Ram serum samples against P. multocida on Nov. 30 
  A n i m a l   I D          
Dilution  3  7 13 14 28 29 31 33 38 40
40  0.5554 0.8746 1.0379 0.6051 0.702 0.9075 0.6673 0.5821 0.5397 0.4351
80 0.6629  0.6412  0.697 0.574 0.6434 0.7202 0.6848 0.5693 0.5606 0.3784
160  0.3854 0.4902 0.6222 0.5301 0.5758 0.5722 0.4914 0.4206 0.3592 0.3151
320  0.2945 0.3402 0.5639 0.3572 0.4178 0.457 0.3019 0.2932 0.2837 0.2903
640  0.2191 0.2634 0.3192 0.2607 0.2676 0.3363 0.226 0.2169  0.155 0.2242
1280  0.2147 0.1978 0.2753 0.1993 0.2076 0.2479 0.1575 0.179  0.1467 0.1493
blank  0.1357 0.1216 0.1257 0.0936 0.0888 0.0726 0.0769 0.0692 0.0759 0.0916
 
Table24 Absorbance of Vaccinated Ram serum samples against P. multocida on Nov. 30 
  A n i m a l   I D          
Dilution 4 6 8 11 16 18 22  32  36 39
40 0.8409  0.7265  0.585 0.6084 0.5308 0.5909 0.4915 0.5819 0.7728 0.5639
80  0.6303 0.5472 0.5404 0.5123 0.587 0.4444 0.4236 0.5252 0.5485 0.3906
160 0.5566  0.437  0.4033 0.4484 0.4844 0.3297 0.3309 0.386  0.4464 0.3302
320 0.4214  0.3496  0.34 0.3729 0.37 0.2919 0.2632 0.3429 0.3379 0.3464
640 0.3131  0.263  0.2658 0.284 0.3203 0.2417 0.1942 0.2765 0.2451 0.226
1280  0.2578 0.1963 0.1879 0.2283 0.2566 0.1826 0.1628 0.2407 0.1787 0.1859
blank  0.077 0.0714 0.0757 0.0855 0.0714 0.0774 0.0738 0.0728 0.0749 0.0704
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Table 25 Absorbance of Control Ram serum samples against M. haemolytica on Dec. 7 
  A n i m a l   I D          
Dilution  3  7 13 14 28 29 31 33 38 40
40  0.2631 0.4252 0.3605 0.7418 0.4705 0.5321 0.8336 0.5602 0.9114 0.6342
80  0.4775 0.4112 0.3412 0.3734 0.5365 0.6271 0.7153 0.6743  0.458 0.6177
160  0.5302 0.4909 0.3758 0.3426 0.5467 0.6066 0.7457 0.537  0.7123 0.9117
320  0.2064 0.1695 0.2059 0.2908 0.251 0.2642 0.1892 0.226  0.3398 0.2535
640  0.1307 0.1684 0.1546 0.1468 0.1718 0.5141 0.1876 0.5998  0.619 0.9749
1280  0.1912 0.1734 0.2677 0.1314 0.2746 0.1382 0.1815 0.1405 0.1648 0.156
blank  0.187 0.0739 0.0623 0.0677 0.0737 0.211 0.1374 0.5964 0.1842 0.2333
 
Table 26 Absorbance of Vaccinated Ram serum samples against M. haemolytica on Dec. 7 
  A n i m a l   I D          
Dilution 4 6 8 11 16 18 22  32  36 39
40  0.4943 0.3597 0.1477 0.1935 0.1848 0.2121 0.1565 0.1524 0.1578 0.0917
80 0.7141  0.217  0.2144 0.232 0.1994 0.1905 0.1681 0.1729 0.1934 0.0929
160  0.6764 0.1702 0.2662 0.241 0.2359 0.1824 0.148 0.2147 0.2046 0.088
320  0.4527 0.2267 0.2261 0.2442 0.2007 0.1683 0.148 0.2042 0.1605 0.0863
640  0.4771 0.1782 0.1881 0.1935 0.1562 0.1597 0.1373 0.164  0.1372 0.082
1280  0.321 0.1604 0.1772 0.1604 0.1172 0.1282 0.0981 0.1219 0.1352 0.084
blank  0.068 0.0615 0.0625 0.0588 0.0638 0.0649 0.0598 0.0617 0.0582 0.0612
 
Table 27 Absorbance of Control Ram serum samples against P. multocida on Dec. 7 
  A n i m a l   I D          
Dilution  3  7 13 14 28 29 31 33 38 40
40  0.336 0.3275 0.3935 0.3048 0.3031 0.3127 0.266 0.2034  0.249 0.2888
80  0.2562 0.3189 0.3981 0.3365 0.327 0.3865 0.2837 0.1557 0.1646 0.2484
160  0.2124 0.2387 0.2613 0.317 0.2601 0.277 0.2294 0.144  0.1228 0.1824
320  0.1514 0.1348 0.2094 0.2148 0.2045 0.2604 0.1562 0.092  0.0996 0.1574
640 0.1299  0.112  0.1676 0.1261 0.1421 0.1852 0.1006 0.0835 0.0816 0.1051
1280  0.1104 0.1011 0.1418 0.1183 0.1275 0.1506 0.0924 0.0716 0.0738 0.128
blank  0.0731 0.0676 0.0751 0.0681 0.0692 0.0681 0.0566 0.0589 0.0572 0.0607
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Table 28 Absorbance of Vaccinated Ram serum samples against P. multocida on Dec. 7 
  A n i m a l   I D          
Dilution 4 6 8 11 16 18 22  32  36 39
40  0.3959 0.1856 0.2281 0.2015 0.1944 0.2111 0.1693 0.1962 0.1941 0.1138
80  0.4005 0.1668 0.2062 0.1711 0.2083 0.1838 0.153 0.1777 0.1749 0.1206
160  0.3124 0.1437 0.1866 0.1392 0.169 0.1525 0.1308 0.1984 0.1467 0.1048
320  0.2632 0.1432 0.1661 0.1395 0.1391 0.1234 0.1131 0.1602 0.1246 0.0911
640  0.2471 0.0985 0.1247 0.1084 0.1178 0.1253 0.0975 0.1445 0.1056 0.0793
1280 0.1723  0.0932  0.086 0.1163 0.1055 0.0954 0.0738 0.1146 0.0907 0.0662
blank  0.0695 0.0875 0.0832 0.0701 0.0708 0.0743 0.06 0.0593 0.0575 0.0588
 
Table 29 Absorbance of Control Ram serum samples against M. haemolytica on Dec. 14 
 
Animal 
I D            
Dilution  3  7 13 14 28 29 31 33 38 40
40  0.7745 0.6469 1.0738 0.7327 0.9857 1.0421 1.1733 1.1153  0.824 0.7635
80 0.6013  0.4145  1.16 0.5485 0.8507 0.7376 1.4002 1.3259 0.6388 0.7001
160 0.6162  0.4185  0.869 0.4653 0.5901 0.5839 0.8041 0.6836 0.3719 0.3532
320  0.5148 0.3557 0.1812 0.3474 0.5967 0.4024 0.5642 0.4761 0.4436 0.2115
640  0.3897 0.2834 0.4486 0.2668 0.3187 0.335 0.3863 0.3776 0.3534 0.3702
1280 0.2902  0.2058  0.116 0.1807 0.3015 0.2699 0.3252 0.2649 0.2556 0.2549
Blank  0.1023 0.1204 0.1065 0.0767 0.1162 0.0838 0.0796 0.0828  0.103 0.1207
 
Table 30 Absorbance of Vaccinated Ram serum samples against M. haemolytica on Dec. 14 
 
Animal 
I D            
Dilution 4 6 8 11 16 18 22  32  36 39
40 1.964  1.508  1.5559 1.3463 1.2775 1.1108 1.3841 1.5459 1.7291 1.1893
80  2.3022 1.2801 1.4221 1.0602 1.1611 1.1108 1.0877 1.4232 1.6097 1.3296
160  2.1495 1.0539 0.4214 1.0157 0.8489 0.805 0.9618 1.1427 1.2002 0.9208
320  1.6586 1.0122 0.9566 0.8185 0.8034 0.6575 0.7932 0.988  0.8617 0.7701
640  1.4999 0.6983 0.6765 0.5257 0.7791 0.379 0.7385 0.6958 0.7935 0.5248
1280  1.5604 0.5619 0.5002 0.6005 0.4291 0.3334 0.4733 0.5153 0.6436 0.4478
Blank  0.2416 0.0885 0.0803 0.0896 0.1031 0.078 0.0736 0.0715 0.0852 0.1026
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Table 31 Absorbance of Control Ram serum samples against P. multocida on Dec. 14 
 
Animal 
I D            
Dilution  3  7 13 14 28 29 31 33 38 40
40  1.3107 1.0641 1.7337 1.0809 1.9964 1.4608 1.4621 1.301  1.2415 1.0039
80 1.1777  0.924  1.4068 0.7102 1.1953 0.8609 1.0103 1.2667 2.2802 1.0328
160  0.6478 0.5935 1.0261 1.7613 0.9361 1.2545 1.1372 1.2805 0.9152 0.7598
320 0.6846  0.4133  0.959 0.5159 0.7422 0.6267 0.5758 0.6576 0.9117 0.5674
640  0.5421 0.3974 0.7146 0.3403 0.5581 0.3746 0.4716 0.4162 0.5144 0.3975
1280  0.4019 0.3047 0.5254 0.3326 0.4249 0.3841 0.3641 0.3338 0.5049 0.3718
Blank  0.6008 0.2237 0.2465 0.2371 0.1965 0.1281 0.1951 0.1946 0.2333 0.3524
 
Table 32 Absorbance of Control Ram serum samples against P. multocida on Dec. 14 
 
Animal 
I D            
Dilution 4 6 8 11 16 18 22  32  36 39
40  1.1153 0.9333 0.9181 0.8121 0.7806 0.7111 0.7316 0.8749 0.8543 0.7951
80  1.0434 0.7195 0.8123 0.7158 0.8229 0.6105 0.6877 0.7489 0.8541 0.6509
160  1.0614 0.6025 0.6992 0.5976 0.6236 0.5831 0.5761 0.5047 0.7307 0.5624
320  0.873 0.4861 0.5524 0.5128 0.4804 0.4535 0.5367 0.4574 0.5841 0.4848
640  0.765 0.4429 0.4033 0.4301 0.4453 0.3052 0.4382 0.3419  0.414 0.3938
1280  0.702 0.3596 0.3496 0.315 0.3652 0.3222 0.3356 0.3193 0.3312 0.3208
Blank  0.1174 0.1295 0.1058 0.1296 0.1054 0.1096 0.1098 0.1139 0.1136 0.1333
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6.2 Specific antibody titers 
 
Table 33 Summary of titers for all animals 
Treatment 
Animal 
ID Sex 
Dates of 
Sampling
Specific 
antibody 
titers 
against M. 
haemolytica. 
Specific 
antibody 
titers 
again P. 
multocida
Control 1  Ewe  Nov.  16  160 640
Control 2  Ewe  Nov.  16  640 320
Control 5  Ewe  Nov.  16  640 640
Control 9  Ewe  Nov.  16  320 320
Control 10  Ewe  Nov.  16  320 640
Control 12  Ewe  Nov.  16  640 320
Control 15  Ewe  Nov.  16  160 160
Control 19  Ewe  Nov.  16  640 640
Control 24  Ewe  Nov.  16  640 320
Control 35  Ewe  Nov.  16  160 320
Vaccinated 17  Ewe  Nov.  16  320 640
Vaccinated 20  Ewe  Nov.  16  1280 640
Vaccinated 21  Ewe  Nov.  16  1280 320
Vaccinated 23  Ewe  Nov.  16  640 1280
Vaccinated 25  Ewe  Nov.  16  320 320
Vaccinated 26  Ewe  Nov.  16  320 1280
Vaccinated 27  Ewe  Nov.  16  320 1280
Vaccinated 30  Ewe  Nov.  16  320 640
Vaccinated 34  Ewe  Nov.  16  160 640
Vaccinated 37  Ewe  Nov.  16  320 640
Control  3 Ram Nov.  16  160 40
Control  7 Ram Nov.  16  80 80
Control  13 Ram Nov.  16  320 80
Control  14 Ram Nov.  16  40 80
Control  28 Ram Nov.  16  320 40
Control  29 Ram Nov.  16  320 80
Control  31 Ram Nov.  16  320 80
Control  33 Ram Nov.  16  40 40
Control  38 Ram Nov.  16  80 320
Control  40 Ram Nov.  16  40 40
Vaccinated  4 Ram Nov.  16  1280 320
Vaccinated  6 Ram Nov.  16  1280 320  44
Table 33 
Continued      
Vaccinated  8 Ram Nov.  16  640 320
Vaccinated  11 Ram Nov.  16  640 320
Vaccinated  16 Ram Nov.  16  640 160
Vaccinated  18 Ram Nov.  16  320 320
Vaccinated  22 Ram Nov.  16  320 320
Vaccinated  32 Ram Nov.  16  640 320
Vaccinated  36 Ram Nov.  16  320 160
Vaccinated  39 Ram Nov.  16  320 80
Control 1  Ewe  Nov.  30  160 160
Control 2  Ewe  Nov.  30  80 160
Control 5  Ewe  Nov.  30  320 320
Control 9  Ewe  Nov.  30  160 160
Control 10  Ewe  Nov.  30  160 160
Control 12  Ewe  Nov.  30  320 320
Control 15  Ewe  Nov.  30  160 320
Control 19  Ewe  Nov.  30  80 160
Control 24  Ewe  Nov.  30  640 640
Control 35  Ewe  Nov.  30  80 320
Vaccinated 17  Ewe  Nov.  30  640 1280
Vaccinated 20  Ewe  Nov.  30  640 1280
Vaccinated 21  Ewe  Nov.  30  1280 640
Vaccinated 23  Ewe  Nov.  30  1280 1280
Vaccinated 25  Ewe  Nov.  30  1280 640
Vaccinated 26  Ewe  Nov.  30  1280 1280
Vaccinated 27  Ewe  Nov.  30  1280 640
Vaccinated 30  Ewe  Nov.  30  1280 640
Vaccinated 34  Ewe  Nov.  30  1280 1280
Vaccinated 37  Ewe  Nov.  30  1280 1280
Control  3 Ram Nov.  30  40 160
Control  7 Ram Nov.  30  160 320
Control  13 Ram Nov.  30  640 640
Control  14 Ram Nov.  30  160 320
Control  28 Ram Nov.  30  320 320
Control  29 Ram Nov.  30  320 640
Control  31 Ram Nov.  30  320 160
Control  33 Ram Nov.  30  80 160
Control  38 Ram Nov.  30  40 160
Control  40 Ram Nov.  30  40 80
Vaccinated  4 Ram Nov.  30  1280 320  45
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Vaccinated  6 Ram Nov.  30  1280 320
Vaccinated  8 Ram Nov.  30  1280 320
Vaccinated  11 Ram Nov.  30  1280 320
Vaccinated  16 Ram Nov.  30  1280 640
Vaccinated  18 Ram Nov.  30  1280 160
Vaccinated  22 Ram Nov.  30  1280 160
Vaccinated  32 Ram Nov.  30  1280 320
Vaccinated  36 Ram Nov.  30  1280 320
Vaccinated  39 Ram Nov.  30  1280 320
Control 1  Ewe  Dec.  7  40 40
Control 2  Ewe  Dec.  7  40 80
Control 5  Ewe  Dec.  7  640 640
Control 9  Ewe  Dec.  7  160 160
Control 10  Ewe  Dec.  7  80 80
Control 12  Ewe  Dec.  7  640 160
Control 15  Ewe  Dec.  7  40 40
Control 19  Ewe  Dec.  7  80 80
Control 24  Ewe  Dec.  7  80 320
Control 35  Ewe  Dec.  7  40 160
Vaccinated 17  Ewe  Dec.  7  160 40
Vaccinated 20  Ewe  Dec.  7  320 160
Vaccinated 21  Ewe  Dec.  7  1280 160
Vaccinated 23  Ewe  Dec.  7  1280 320
Vaccinated 25  Ewe  Dec.  7  1280 160
Vaccinated 26  Ewe  Dec.  7  1280 320
Vaccinated 27  Ewe  Dec.  7  640 80
Vaccinated 30  Ewe  Dec.  7  160 160
Vaccinated 34  Ewe  Dec.  7  40 80
Vaccinated 37  Ewe  Dec.  7  320 160
Control  3 Ram Dec.  7  160 160
Control  7 Ram Dec.  7  160 160
Control  13 Ram Dec.  7  160 640
Control  14 Ram Dec.  7  160 320
Control  28 Ram Dec.  7  160 320
Control  29 Ram Dec.  7  160 640
Control  31 Ram Dec.  7  160 160
Control  33 Ram Dec.  7  160 40
Control  38 Ram Dec.  7  320 80
Control  40 Ram Dec.  7  160 160  46
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Vaccinated  4 Ram Dec.  7  640 1280
Vaccinated  6 Ram Dec.  7  40 80
Vaccinated  8 Ram Dec.  7  40 320
Vaccinated  11 Ram Dec.  7  40 80
Vaccinated  16 Ram Dec.  7  40 160
Vaccinated  18 Ram Dec.  7  40 80
Vaccinated  22 Ram Dec.  7  40 40
Vaccinated  32 Ram Dec.  7  40 160
Vaccinated  36 Ram Dec.  7  40 80
Vaccinated  39 Ram Dec.  7  40 40
Control 1  Ewe  Dec.  24  40 80
Control 2  Ewe  Dec.  24  160 320
Control 5  Ewe  Dec.  24  80 320
Control 9  Ewe  Dec.  24  80 160
Control 10  Ewe  Dec.  24  80 160
Control 12  Ewe  Dec.  24  160 320
Control 15  Ewe  Dec.  24  80 320
Control 19  Ewe  Dec.  24  160 640
Control 24  Ewe  Dec.  24  640 320
Control 35  Ewe  Dec.  24  80 320
Vaccinated 17  Ewe  Dec.  24  1280 1280
Vaccinated 20  Ewe  Dec.  24  640 1280
Vaccinated 21  Ewe  Dec.  24  640 1280
Vaccinated 23  Ewe  Dec.  24  640 1280
Vaccinated 25  Ewe  Dec.  24  640 1280
Vaccinated 26  Ewe  Dec.  24  640 640
Vaccinated 27  Ewe  Dec.  24  640 1280
Vaccinated 30  Ewe  Dec.  24  320 1280
Vaccinated 34  Ewe  Dec.  24  640 1280
Vaccinated 37  Ewe  Dec.  24  320 1280
Control  3 Ram Dec.  24  320 640
Control  7 Ram Dec.  24  40 160
Control  13 Ram Dec.  24  640 640
Control  14 Ram Dec.  24  160 160
Control  28 Ram Dec.  24  320 640
Control  29 Ram Dec.  24  160 320
Control  31 Ram Dec.  24  320 320
Control  33 Ram Dec.  24  320 320
Control  38 Ram Dec.  24  320 320  47
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Control  40 Ram Dec.  24  80 320
Vaccinated  4 Ram Dec.  24  1280 1280
Vaccinated  6 Ram Dec.  24  1280 160
Vaccinated  8 Ram Dec.  24  1280 320
Vaccinated  11 Ram Dec.  24  1280 160
Vaccinated  16 Ram Dec.  24  1280 160
Vaccinated  18 Ram Dec.  24  320 160
Vaccinated  22 Ram Dec.  24  1280 320
Vaccinated  32 Ram Dec.  24  1280 80
Vaccinated  36 Ram Dec.  24  1280 320
Vaccinated  39 Ram Dec.  24  1280 160
 